A
Aerska
Ireland · Biotech
Aerska develops RNA medicines for neurological diseases using delivery technology designed to carry treatments across the blood-brain barrier.
Product
The Dublin biotechnology company, with research operations in London, develops brain shuttle technology to deliver RNA interference medicines to the central nervous system. Its antibody-oligo conjugate platform is being advanced toward clinical development.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| Series A | $39M | age1 — LeadEQT Dementia Fund — LeadIaso Ventures — Participant |